Skip to main content
. 2017 Nov 3;19(11):e373. doi: 10.2196/jmir.8602

Table 2.

Treatment received in the intention-to-treat samples.

Therapy Total sample (N=164) Per-protocol sample (n=117)

Smartphone CBT + medication change (n=81) Medication change alone (n=83) Smartphone CBT + medication change (n=60) Medication change alone (n=57)
Pharmacotherapy




Discontinuation of protocol antidepressant treatment by escitalopram or sertraline by week 9, n (%) 16 (20) 14 (17) 10 (17) 8 (14)

Discontinuation reason, n





Prescription of prohibited drugs 6 9 4 5


Amelioration 1 1 1


Deterioration 1 1


Side effects 3 1 1


Other 5 3 4 2

Discontinuation of any antidepressant therapy by week 9, n (%) 5 (6) 2 (2) 2 (3) 2 (4)

Escitalopram dosage at week 9 (mg/day), mean (SD) 9.5 (3.0), n=48 10.0 (3.2), n=49 9.7 (3.1), n=38 10.1 (2.9), n=34

Sertraline dosage at week 9 (mg/day), mean (SD) 79.0 (26.7), n=25 83.6 (23.4), n=29 81.6 (26.1), n=19 83.0 (24.9), n=22
Smartphone CBT




Sessions completed, n



0 1



3 1
1


4 4
3


5 4
2


6 11
8


7 17
13


8 43
33

Time per session (days), mean (SD) 10.8 (4.2) 10.7 (4.0)

Number of mind maps for self-monitoring, mean (SD) 11.2 (11.4) 10.8 (10.3)

Number of behavioral activation tasks, mean (SD) 14.4 (17.1) 14.6 (17.8)

Number of alternative thoughts, mean (SD) 6.1 (6.0) 6.5 (6.0)